$70.09-1.64 (-2.29%)
Merit Medical Systems, Inc.
Merit Medical Systems, Inc. in the Healthcare sector is trading at $70.09 with a market capitalization of $4.2B. Wall Street consensus targets $89.55 (11 analysts), implying a +27.8% move over the next 12 months. The stock is currently 28% below its 52-week high of $96.74, remaining 9.0% below its 200-day moving average. On fundamentals, Piotroski 7/9 indicates strong financial quality, Altman Z in the safe zone. The Whystock Score of 90/100 reflects bullish alignment across trend, valuation and analyst targets.
| Metric (USD) | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| Total Revenue | $381.88Mβ | $393.94Mβ | $384.16Mβ | $382.46Mβ | $355.35M |
| Gross Profit | $184.80Mβ | $195.35Mβ | $186.41Mβ | $184.49Mβ | $172.02M |
| Operating Income | $43.98Mβ | $53.98Mβ | $42.64Mβ | $47.02Mβ | $42.06M |
| Net Income | $40.99Mβ | $38.01Mβ | $27.75Mβ | $32.58Mβ | $30.15M |
Merit Medical Systems, Inc. designs, develops, manufactures, and markets single-use medical products for interventional, diagnostic, and therapeutic procedures in the United States, China, Japan, Germany, France, the United Kingdom, and international...
Many small-cap stocks have limited Wall Street coverage, giving savvy investors the chance to act before everyone else catches on. But the flip side is that these businesses have increased downside risk because they lack the scale and staying power of their larger competitors.
Wrapping up Q1 earnings, we look at the numbers and key takeaways for the medical devices & supplies - cardiology, neurology, vascular stocks, including Merit Medical Systems (NASDAQ:MMSI) and its peers.
From novel pharmaceuticals to telemedicine, most healthcare companies are on a mission to drive better patient outcomes. Shareholders who bet on the industry have seen decent returns lately as healthcare stocks were up 6.4% over the past six months, almost identical to the S&P 500.
Investors need to pay close attention to MMSI stock based on the movements in the options market lately.
MMSI leans on therapeutic strength, an oncology acquisition and a new stent launch, but tariffs, OEM weakness and China pressure shadow 2026.